IMPORTANT DRUG WARNING

03 March 2006

Dear Health Care Professional:

Ligand Pharmaceuticals Inc. is writing to inform you of changes to the product labeling for ONTAK® (denileukin diftitox). These changes are being made to alert physicians/health care professionals to new post-marketing adverse events.

The following new information has been added to the Package Insert for ONTAK®.

- The following statement has been added under **WARNINGS:**

  Visual Loss: Loss of visual acuity usually with loss of color vision with or without retinal pigment mottling has been reported following administration of ONTAK®. Recovery was reported in some of the affected patients; however, most patients reported persistent visual impairment.

- The following statements have been added under **ADVERSE REACTIONS:**

  Post-Marketing:

  The following adverse reactions have been identified during post approval use of ONTAK®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

  Special Senses: See **WARNINGS: Visual Loss**

Please refer to the accompanying revised full prescribing information for ONTAK®, including boxed warning.

If you have any questions or are aware of adverse events related to ONTAK®, please contact Ligand Professional Services at 1-800-964-5836.

Sincerely,

Richard Ghalie, M.D.
Vice President, Medical Affairs and Professional Services
Ligand Pharmaceuticals Inc.